Intraocular Inflammation Following Faricimab Intravitreal Injection Treated With Sub-tenon Triamcinolone Acetonide Injection

We report the management of intraocular inflammation (IOI) following faricimab intravitreal injection. Severe IOI was observed in three eyes (one eye with age-related macular degeneration (AMD) and two eyes in the same patient with diabetic macular edema (DME)). These three eyes had fine keratic precipitates, inflammatory cells in the anterior chamber, and vitreous opacity, with decreased best-corrected visual acuity (BCVA) in all patients. Blood tests did not reveal any abnormalities, and anterior chamber multiplex polymerase chain reaction and bacterial cultures were negative. Sub-tenon triamcinolone acetonide (STTA) injections improved anterior inflammation, vitreous opacity, and BCVA, although posterior iris synechia caused by inflammation persisted in one patient. Faricimab injection can induce IOI. In this study, IOI was managed with a STTA injection during the early stage of uveitis. Severe inflammation can lead to complications such as posterior iris synechia.